Microbiology of newer fluoroquinolones: Focus on respiratory pathogens

Diagnostic Microbiology and Infectious Disease

Volumn 44, Issue 3, 2002, Pages 213-220

  Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fluoroquinolone antimicrobials; Gemifloxacin; Microbiology; Resistance; Respiratory pathogens

Indexed keywords

BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; MACROLIDE; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIUM ISOLATE; CHRONIC BRONCHITIS; CLINICAL PRACTICE; DISEASE ASSOCIATION; HAEMOPHILUS INFLUENZAE; HUMAN; IN VITRO STUDY; MICROBIOLOGY; NONHUMAN; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SINUSITIS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; RESPIRATORY TRACT INFECTIONS;

EID: 0036863726     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(02)00436-4     Document Type: Review

References (69)

1. Adams P.F., Hendershot G.E., Marano M.A. Current estimates from the National Health Interview Survey, 1996. National Center for Health Statistics Vital Health Statistics. 10:1999;200.
2. Ball P., Make B. Acute exacerbations of chronic bronchitis an international comparison . Chest. 113:(Suppl):1998;199S-204S.
3. Bartlett J.G. Empirical therapy of community-acquired pneumonia macrolides are not ideal choices . Seminars in Respiratory Infection. 12:1997;329-333.
4. Bartlett J.G., Dowell S.F., Mandell L.A., File T.M. Jr, Musher D.M., Fine M.J. Practice guidelines for the management of community-acquired pneumonia in adults Infectious Diseases Society of America . Clinical Infectious Diseases. 31:2000;347-382.
5. Bast D.J., Low D.E., Duncan C.L., Kilburn L., Mandell L.A., Davidson R.J., de Azavedo J.C. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae contributions of type II topoisomerase mutations and efflux to levels of resistance . Antimicrobial Agents and Chemotherapy. 44:2000;3049-3054.
6. Biedenbach D.J., Jones R.N. Fluoroquinolone-resistant Haemophilus influenzae frequency of occurrence and analysis of confirmed strains in the SENTRY Antimicrobial Surveillance Program (North and Latin America) . Diagnostic Microbiology and Infectious Disease. 36:2000;255-259.
7. Biedenbach D.J., Jones R.N., Pfaller M.A. Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis report from the SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States . Diagnostic Microbiology and Infectious Disease. 39:2001;245-250.
8. Breiman R.F., Butler J.C., Tenover F.C., Elliott J.A., Facklam R.R. Emergence of drug-resistant pneumococcal infections in the United States. JAMA. 271:1994;1831-1835.
9. Broskey J., Coleman K., Gwynn M.N., McCloskey L., Traini C., Voelker L., Warren R. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy. 45:(Suppl S1):2000;95-99.
10. Brown P.D., Lerner S.A. Community-acquired pneumonia. Lancet. 352:1998;1295-1302.
11. Campbell G.D. Jr, Silberman R. Drug-resistant Streptococcus pneumoniae. Clinical Infectious Diseases. 26:1998;1188-1195.
12. Premature deaths, monthly mortality, and monthly physician contacts - United States. MMWR Morbidity and Mortality Weekly Report. 46:1997;556-561.
13. Chen D.K., McGeer A., de Azavedo J.C., Low D.E. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. New England Journal of Medicine. 341:1999;233-239.
14. Cormican M.G., Jones R.N. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone. Antimicrobial Agents and Chemotherapy. 41:1997;204-211.
15. Davies T.A., Kelly L.M., Pankuch G.A., Credito K.L., Jacobs M.R., Appelbaum P.C. Antipneumococcal activities of gemifloxacin compared to those of nine other agents. Antimicrobial Agents and Chemotherapy. 44:2000;304-310.
16. Davies T.A., Kelly L.M., Hoellman D.B., Ednie L.M., Clark C.L., Bajaksouzian S., Jacobs M.R., Appelbaum P.C. Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis. Antimicrobial Agents and Chemotherapy. 44:2000;633-639.
17. Davies T.A., Pankuch G.A., Dewasse B.E., Jacobs M.R., Appelbaum P.C. In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy. 43:1999;1177-1182.
18. Deshpande L.M., Jones R.N. Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999). Diagnostic Microbiology and Infectious Disease. 37:2000;139-142.
19. Doern G.V., Heilmann K.P., Huynh H.K., Rhomberg P.R., Coffman S.L., Brueggemann A.B. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrobial Agents and Chemotherapy. 45:2001;1721-1729.
20. Doern G.V., Jones R.N., Pfaller M.A., Kugler K. Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Antimicrobial Agents and Chemotherapy. 43:1999;385-389.
21. Doern G.V., Pfaller M.A., Kugler K., Freeman J., Jones R.N. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America 1997 results from the SENTRY Antimicrobial Surveillance Program . Clinical Infectious Disease. 27:1998;764-770.
22. Domagala J.M. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. Journal of Antimicrobial Chemotherapy. 33:1994;685-706.
23. Donati M., Rodriquez Fermepin M., Olmo A., D'Apote L., Cevenini R. Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp. Journal of Antimicrobial Chemotherapy. 43:1999;825-827.
24. Drlica K., Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiology and Molecular Biology Reviews. 61:1997;377-392.
25. Dubois J., St-Pierre C. Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp. Journal of Antimicrobial Chemotherapy. 45:(Suppl 1):2000;41-46.
26. Duffy L.B., Crabb D., Searcey K., Kempf M.C. Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp. Journal of Antimicrobial Chemotherapy. 45:(Suppl 1):2000;29-33.
27. Entenza J.M., Que Y.A., Cottagnoud P., Giddey M., Glauser M.P., Moreillon P. In vitro selection of resistance to ciprofloxacin, trovafloxacin and gemifloxacin in Streptococcus pneumoniae, and analysis of corresponding mutations in topoisomerase genes. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2000;. September 17-20, Toronto, Canada.
28. Esposito S., Noviello S., Ianniello F. Comparative in vitro activity of older and newer fluoroquinolones against respiratory tract pathogens. Chemotherapy. 46:2000;309-314.
29. Fuchs P.C., Barry A.L., Brown S.D. In vitro activity of gemifloxacin against contemporary clinical bacterial isolates from eleven North American medical centers, and assessment of disk diffusion test interpretive criteria. Diagnostic Microbiology and Infectious Disease. 38:2000;243-253.
30. Fuentes F., Giménez M.J., Marco F., Alou L., Aguilar L., Prieto J. In vitro susceptibility to gemifloxacin and trovafloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin. European Journal of Clinical Microbiology & Infectious Diseases. 19:2000;137-139.
31. Fung-Tomc J.C., Minassian B., Kolek B., Huczko E., Aleksunes L., Stickle T., Washo T., Gradelski E., Valera L., Bonner D.P. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrobial Agents and Chemotherapy. 44:2000;3351-3356.
32. Garcia M.T., Pelaz C., Giménez M.J., Aguilar L. In vitro activities of gemifloxacin versus five quinolones and two macrolides against 271 Spanish isolates of Legionella pneumophila influence of charcoal on susceptibility test results . Antimicrobial Agents and Chemotherapy. 44:2000;2176-2178.
33. Grossman R.F. Guidelines for the treatment of acute exacerbations of chronic bronchitis. Chest. 112:(6 Suppl):1997;310S-313S.
34. Hoban D.J., Doern G.V., Fluit A.C., Roussel-Delvallez M., Jones R.N. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clinical Infectious Diseases. 32:(Suppl 2):2001;S81-S93.
35. Hoban D.J., Bouchillon S.K., Karlowsky J.A., Johnson J.L., Butler D.L., Miller L.A., Poupard J.A. A comparative in vitro surveillance study of gemifloxacin activities against 2,632 recent Streptococcus pneumoniae isolates from across Europe, North America, and South America. Antimicrobial Agents and Chemotherapy. 44:2000;3008-3011.
36. Hooper D.C. How the quinolones have come of age. American Journal of Medicine. 2002;. (in press).
37. Hooper D.C. Quinolones. Mandell G.L., Bennett J.E. Principles and Practice of Infectious Diseases. 2000;404-423 Churchill Livingstone, Philadelphia, PA.
38. Jacobs M.R., Bajaksouzian S., Zilles A., Lin G., Pankuch G.A., Appelbaum P.C. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters 1997 US surveillance study . Antimicrobial Agents and Chemotherapy. 43:1999;1901-1908.
39. Johnson D.M., Jones R.N., Erwin M.E. Anti-streptococcal activity of SB-265805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelines. Diagnostic Microbiology and Infectious Disease. 33:1999;87-91.
40. Jolley A., Andrews J.M., Brenwald N., Wise R. The in-vitro activity of a new highly active quinolone, DU-6859a. Journal of Antimicrobial Chemotherapy. 32:1993;757-763.
41. Jones R.N. The impact of antimicrobial resistance changing epidemiology of community-acquired respiratory-tract infections . American Journal of Health-System Pharmacy. 56:(22 Suppl 3):1999;S4-S11.
42. Jones R.N., Pfaller M.A. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance data from the SENTRY Antimicrobial Surveillance Program . Clinical Infectious Diseases. 31:(Suppl. 2):2000;S16-S23.
43. Jones R.N., Pfaller M.A., Stilwell M. Activity and spectrum of BMS 284756, a new des-F(6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci. Diagnostic Microbiology and Infectious Disease. 39:2001;133-135.
44. Jones R.N., Croco M.A.T., Kugler K.C., Pfaller M.A., Beach M.L. Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997) . Diagnostic Microbiology and Infectious Disease. 37:2000;115-125.
45. Jones R.N., Pfaller M.A., Erwin M.E. Evaluation of gemifloxacin (SB-265805, LB20304a) in vitro activity against over 6000 gram-positive pathogens from diverse geographic areas . International Journal of Antimicrobial Agents. 15:2000;227-230.
46. Jorgensen J.H., Weigel L.M., Swenson J.M., Whitney C.G., Ferraro M.J., Tenover F.C. Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy. 44:2000;2962-2968.
47. Jorgensen J.H., Weigel L.M., Ferraro M.J., Swenson J.M., Tenover F.C. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci. Antimicrobial Agents and Chemotherapy. 43:1999;329-334.
48. Kitzis M.D., Goldstein F.W., Miegi M., Acar J.F. In-vitro activity of levofloxacin, a new fluoroquinolone evaluation against Haemophilus influenzae and Moraxella catarrhalis . Journal of Antimicrobial Chemotherapy. 43:(Suppl C):1999;21-26.
49. Kitzis M.D., Varon E., Gutmann L., Goldstein F. Comparative in vitro activity of gemifloxacin against multi-resistant strains of Streptococcus pneumoniae. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1999;. September 26-29, San Francisco, CA.
50. Lemmen S., Al-Lahham A., Lütticken R., Reinert R.R. In vitro activity of gemifloxacin against Streptococcus pneumoniae isolates in Germany. Chemotherapy. 47:2001;104-109.
51. Marchese A., Debbia E.A., Schito G.C. Comparative in vitro potency of gemifloxacin against European respiratory tract pathogens isolated in the Alexander Project. Journal of Antimicrobial Chemotherapy. 46:(Topic T1):2000;11-15.
52. Marshall S.A., Jones R.N. In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone. Antimicrobial Agents and Chemotherapy. 37:1993;2747-2753.
53. Marshall S.A., Jones R.N., Murray P.R., Washington J.A., Allen S.D., Gerlach E.H., Erwin M.E. In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolates. Journal of Antimicrobial Chemotherapy. 32:1993;877-884.
54. Mathai D., Lewis M.T., Kugler K.C., Pfaller M.A., Jones R.N. Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia, I: results from the SENTRY Antimicrobial Surveillance Program (North America, 1998). Diagnostic Microbiology and Infectious Disease. 39:1998;105-116.
55. Milatovic D., Schmitz F-J, Brisse S., Verhoef J., Fluit A.C. In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates. Antimicrobial Agents and Chemotherapy. 44:2000;1102-1107.
56. Miyashita N., Niki Y., Kishimoto T., Nakajima M., Matsushima T. In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp. Antimicrobial Agents and Chemotherapy. 41:1997;1331-1334.
57. Performance Standards for Antimicrobial Susceptibility Testing; Twelfth Informational Supplement. M100-S12. 2002;NCCLS, Wayne, PA.
58. Niederman M.S., Mandell L.A., Anzueto A., Bass J.B., Broughton W.A., Campbell G.D., Dean N., File T., File M.J., Gross P.A., Martinez F., Marrie T.J., Plouffe J.F., Ramirez J., Sarosi G.A., Torres A., Wilson R., Yu V.L. Guidelines for the management of adults with community-acquired pneumonia diagnosis, assessment of severity, antimicrobial therapy, and prevention . American Journal of Respiratory Critical Care Medicine. 163:2001;1730-1754.
59. Pestova E., Beyer R., Cianciotto N.P., Noskin G.A., Peterson L.R. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones. Antimicrobial Agents and Chemotherapy. 43:1999;2000-2004.
60. Rhomberg P.R., Biedenbach D.J., Jones R.N. Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp. Diagnostic Microbiology and Infectious Disease. 40:2001;45-49.
61. Rittenhouse S., McCloskey L., Broskey J., Niconovich N., Jakielaszek C., Poupard J., Coleman K. In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens. Journal of Antimicrobial Chemotherapy. 45:(Suppl S1):2000;23-27.
62. Roblin P.M., Hammerschlag M.R. In-vitro activity of gatifloxacin against Chlamydia trachomatis and Chlamydia pneumoniae. Journal of Antimicrobial Chemotherapy. 44:1999;549-551.
63. Roblin P.M., Reznik T., Kutlin A., Hammerschlag M.R. In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae. Antimicrobial Agents and Chemotherapy. 43:1999;2806-2807.
64. Sens K., Mietzner S., Sagnimeni A., Stout J.E., Yu V.L. Activity of new quinolones, macrolide, and ketolide against 100 strains of Legionella species using broth dilution and intracellular susceptibility testing methods. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2000;. September 17-20, Toronto, Canada.
65. Gales A., Sader H., Jones R.N. Activities of BMS 284756 (T-3811) against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from SENTRY Antimicrobial Surveillance Program medical centers in Latin America (1999). Antimicrobial Agents and Chemotherapy. 45:2001;1463-1466.
66. Shortridge V.D., Doern G.V., Brueggemann A.B., Beyer J.M., Flamm R.K. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clinical Infectious Diseases. 29:1999;1186-1188.
67. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngology - Head & Neck Surgery. 123:(1 Pt 2):2000;S1-S32.
68. Takahata M., Mitsuyama J., Yamashiro Y., Yonezawa M., Araki H., Todo Y., Minami S., Watanabe Y., Narita H. In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Antimicrobial Agents and Chemotherapy. 43:1999;1077-1084.
69. Takahata M., Shimakura M., Hori R., Kizawa K., Todo Y., Minami S., Watanabe Y., Narita H. In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae. Antimicrobial Agents and Chemotherapy. 45:2001;312-315.